- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Science, Complicated Pharmacology, Patient Relationships Drew Alan Moss, M.D., to Crohn’s and Colitis
The new chief scientific officer of the Crohn’s and Colitis Foundation talked about what motivated him to pursue a career researching and taking care of Crohn’s and colitis patients.
First of five parts
In an era of U.S. healthcare that can make for fleeting and fragmented relationships between patients and clinicians, Alan Moss, M.D., has had different experience, sometimes seeing patients over many years and different stages of their lives.
“I have had patients who were in high school, then they’re in college, and (then) they’re trying to carve out a career, they’re getting pregnant. And all those things bring up a whole new batch of questions,” Moss said in a recent wide-ranging interview with Managed Healthcare Executive.
The Crohn’s and Colitis Foundation announced on Sept. 25 that Moss had been named the organization’s chief scientific officer. Moss is also the director of the Crohn’s & Colitis Program at Boston Medical Center. Prior to Boston Medical Center, he conducted research and took care of patients at Beth Israel Deaconess Medical Center, which is also in Boston.
In addition to the enduring patient relationship, Moss said he was draw to a career in inflammatory bowel disease care and research by complexities of the scientific understanding of Crohn’s disease and ulcerative colitis and the pharmacology of the treatments.
In this video segment of his conversation with MHE, Moss also discusses the research, education and advocacy aspects of his new job at the Crohn’s and Colitis Foundation.
